Journal of oral rehabilitation · 2026
Prevalence of Dysgeusia in Head and Neck Cancer Patients: A Meta-Analysis and Moderator Analysis.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Afiyanti Yati, Mandasari Masita, Lestari Sri Rahayu, Nasution Lina Anisa, Gautama Made Satya Nugraha, Susiladewi Ida Ayu Md Vera, Fitriani Hemi, Merdawati Leni, Yona Sri, Ye Jia-You, Arifin Hidayat
Аннотация
BACKGROUND: Dysgeusia is a frequent yet underrecognised complication among head and neck cancer (HNC) patients, adversely affecting nutritional intake, psychological well-being and quality of life. Accurate prevalence estimates are essential to guide supportive care interventions.
OBJECTIVE: This meta-analysis aimed to determine the global pooled prevalence of dysgeusia in HNC patients and identify potential moderators influencing prevalence estimates.
MATERIALS AND METHODS: A systematic review and meta-analysis was conducted following MOOSE and PRISMA 2020 guidelines. Online databases were searched in March 2024 across Embase, PubMed and Scopus without restrictions on region, language, or publication year. Eligible studies reported prevalence of dysgeusia using subjective or objective assessments. Pooled prevalence was estimated using a generalised linear mixed model with a random-effects approach. Heterogeneity was assessed with I2 and Q statistics. Moderator analyses explored sources of heterogeneity.
RESULTS: Twenty-three studies involving 4805 HNC patients (mean age 59.8 ± 13.1 years) were included. The pooled prevalence of dysgeusia was 42.7% (95% CI, 29.7-56.9; n = 2099). Sensitivity analyses confirmed the robustness of these findings. The highest prevalence was observed in Asia (52.7%), followed by North America (41.4%) and South America (37.5%). Moderator analysis showed that older age, male sex, advanced disease stage (III-IV) and the use of diverse measurement tools significantly moderated the pooled prevalence of dysgeusia.
CONCLUSIONS: Dysgeusia affects approximately half of HNC patients. Incorporating routine screening and targeted management of dysgeusia into survivorship care may help reduce nutritional risks, improve quality of life and support long-term rehabilitation.
CLINICAL SIGNIFICANCE: Dysgeusia is highly prevalent in HNC patients, with important implications for nutrition, adherence to treatment and psychosocial well-being. Routine assessment and evidence-based interventions for dysgeusia should be integrated into multidisciplinary oral rehabilitation programmes to optimise patient outcomes.
OBJECTIVE: This meta-analysis aimed to determine the global pooled prevalence of dysgeusia in HNC patients and identify potential moderators influencing prevalence estimates.
MATERIALS AND METHODS: A systematic review and meta-analysis was conducted following MOOSE and PRISMA 2020 guidelines. Online databases were searched in March 2024 across Embase, PubMed and Scopus without restrictions on region, language, or publication year. Eligible studies reported prevalence of dysgeusia using subjective or objective assessments. Pooled prevalence was estimated using a generalised linear mixed model with a random-effects approach. Heterogeneity was assessed with I2 and Q statistics. Moderator analyses explored sources of heterogeneity.
RESULTS: Twenty-three studies involving 4805 HNC patients (mean age 59.8 ± 13.1 years) were included. The pooled prevalence of dysgeusia was 42.7% (95% CI, 29.7-56.9; n = 2099). Sensitivity analyses confirmed the robustness of these findings. The highest prevalence was observed in Asia (52.7%), followed by North America (41.4%) and South America (37.5%). Moderator analysis showed that older age, male sex, advanced disease stage (III-IV) and the use of diverse measurement tools significantly moderated the pooled prevalence of dysgeusia.
CONCLUSIONS: Dysgeusia affects approximately half of HNC patients. Incorporating routine screening and targeted management of dysgeusia into survivorship care may help reduce nutritional risks, improve quality of life and support long-term rehabilitation.
CLINICAL SIGNIFICANCE: Dysgeusia is highly prevalent in HNC patients, with important implications for nutrition, adherence to treatment and psychosocial well-being. Routine assessment and evidence-based interventions for dysgeusia should be integrated into multidisciplinary oral rehabilitation programmes to optimise patient outcomes.